The Experts below are selected from a list of 41133 Experts worldwide ranked by ideXlab platform
Jun-ichiro Hamada - One of the best experts on this subject based on the ideXlab platform.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese Journal of Clinical Oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:Methods: We evaluated the O 6 -methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. Results: Methylation-specific PCR assay demonstrated that the status of O 6 -methylguanineDNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O 6 -methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P ¼ 0.016). O 6 methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P ¼ 0.012). Conclusions: Our results give the evidence that the increase of O 6 -methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese journal of clinical oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:BACKGROUND The DNA repair protein O(6)-methylguanine-DNA Methyltransferase is a drug-resistant protein, which protects the tumors from chemotherapeutic alkylating agents, such as temozolomide. The methylation status of O(6)-methylguanine-DNA Methyltransferase promoter has been shown to be a major predictive factor for clinical outcome in glioma patients when treated by alkylating agents. Thereby, there were many reports on O(6)-methylguanine-DNA Methyltransferase promoter methylation and mRNA expression in primary glioma, in contrast, there were only a few studies in recurrent glioma. METHODS We evaluated the O(6)-methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. RESULTS Methylation-specific PCR assay demonstrated that the status of O(6)-methylguanine-DNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O(6)-methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P = 0.016). O(6)-methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P = 0.012). CONCLUSIONS Our results give the evidence that the increase of O(6)-methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
Tomohide Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese Journal of Clinical Oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:Methods: We evaluated the O 6 -methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. Results: Methylation-specific PCR assay demonstrated that the status of O 6 -methylguanineDNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O 6 -methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P ¼ 0.016). O 6 methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P ¼ 0.012). Conclusions: Our results give the evidence that the increase of O 6 -methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese journal of clinical oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:BACKGROUND The DNA repair protein O(6)-methylguanine-DNA Methyltransferase is a drug-resistant protein, which protects the tumors from chemotherapeutic alkylating agents, such as temozolomide. The methylation status of O(6)-methylguanine-DNA Methyltransferase promoter has been shown to be a major predictive factor for clinical outcome in glioma patients when treated by alkylating agents. Thereby, there were many reports on O(6)-methylguanine-DNA Methyltransferase promoter methylation and mRNA expression in primary glioma, in contrast, there were only a few studies in recurrent glioma. METHODS We evaluated the O(6)-methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. RESULTS Methylation-specific PCR assay demonstrated that the status of O(6)-methylguanine-DNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O(6)-methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P = 0.016). O(6)-methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P = 0.012). CONCLUSIONS Our results give the evidence that the increase of O(6)-methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
Yutaka Hayashi - One of the best experts on this subject based on the ideXlab platform.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese Journal of Clinical Oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:Methods: We evaluated the O 6 -methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. Results: Methylation-specific PCR assay demonstrated that the status of O 6 -methylguanineDNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O 6 -methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P ¼ 0.016). O 6 methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P ¼ 0.012). Conclusions: Our results give the evidence that the increase of O 6 -methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese journal of clinical oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:BACKGROUND The DNA repair protein O(6)-methylguanine-DNA Methyltransferase is a drug-resistant protein, which protects the tumors from chemotherapeutic alkylating agents, such as temozolomide. The methylation status of O(6)-methylguanine-DNA Methyltransferase promoter has been shown to be a major predictive factor for clinical outcome in glioma patients when treated by alkylating agents. Thereby, there were many reports on O(6)-methylguanine-DNA Methyltransferase promoter methylation and mRNA expression in primary glioma, in contrast, there were only a few studies in recurrent glioma. METHODS We evaluated the O(6)-methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. RESULTS Methylation-specific PCR assay demonstrated that the status of O(6)-methylguanine-DNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O(6)-methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P = 0.016). O(6)-methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P = 0.012). CONCLUSIONS Our results give the evidence that the increase of O(6)-methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
Yuya Yoshida - One of the best experts on this subject based on the ideXlab platform.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese Journal of Clinical Oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:Methods: We evaluated the O 6 -methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. Results: Methylation-specific PCR assay demonstrated that the status of O 6 -methylguanineDNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O 6 -methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P ¼ 0.016). O 6 methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P ¼ 0.012). Conclusions: Our results give the evidence that the increase of O 6 -methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese journal of clinical oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:BACKGROUND The DNA repair protein O(6)-methylguanine-DNA Methyltransferase is a drug-resistant protein, which protects the tumors from chemotherapeutic alkylating agents, such as temozolomide. The methylation status of O(6)-methylguanine-DNA Methyltransferase promoter has been shown to be a major predictive factor for clinical outcome in glioma patients when treated by alkylating agents. Thereby, there were many reports on O(6)-methylguanine-DNA Methyltransferase promoter methylation and mRNA expression in primary glioma, in contrast, there were only a few studies in recurrent glioma. METHODS We evaluated the O(6)-methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. RESULTS Methylation-specific PCR assay demonstrated that the status of O(6)-methylguanine-DNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O(6)-methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P = 0.016). O(6)-methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P = 0.012). CONCLUSIONS Our results give the evidence that the increase of O(6)-methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
Mitsutoshi Nakada - One of the best experts on this subject based on the ideXlab platform.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese Journal of Clinical Oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:Methods: We evaluated the O 6 -methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. Results: Methylation-specific PCR assay demonstrated that the status of O 6 -methylguanineDNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O 6 -methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P ¼ 0.016). O 6 methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P ¼ 0.012). Conclusions: Our results give the evidence that the increase of O 6 -methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.
-
The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma
Japanese journal of clinical oncology, 2010Co-Authors: Tomohide Suzuki, Emi Nambu, Natsuki Furuyama, Daisuke Kita, Yasuhiko Hayashi, Yuya Yoshida, Yutaka Hayashi, Mitsutoshi Nakada, Jun-ichiro HamadaAbstract:BACKGROUND The DNA repair protein O(6)-methylguanine-DNA Methyltransferase is a drug-resistant protein, which protects the tumors from chemotherapeutic alkylating agents, such as temozolomide. The methylation status of O(6)-methylguanine-DNA Methyltransferase promoter has been shown to be a major predictive factor for clinical outcome in glioma patients when treated by alkylating agents. Thereby, there were many reports on O(6)-methylguanine-DNA Methyltransferase promoter methylation and mRNA expression in primary glioma, in contrast, there were only a few studies in recurrent glioma. METHODS We evaluated the O(6)-methylguanine-DNA Methyltransferase mRNA expression and promoter methylation status in glioma patients before and after recurrence by quantitative real-time PCR and methylation-specific PCR assay. Thirteen paired primary and recurrent glioma patients were analyzed, including four patients in whom malignant transformation occurred from Grade II to Grade III. RESULTS Methylation-specific PCR assay demonstrated that the status of O(6)-methylguanine-DNA Methyltransferase promoter changed from methylated to unmethylated in 10 of 13 samples when the tumor relapsed. Moreover, intra-individual O(6)-methylguanine-DNA Methyltransferase mRNA level increased in recurrent gliomas than in primary ones (P = 0.016). O(6)-methylguanine-DNA Methyltransferase mRNA level was correlated with the methylation status (P = 0.012). CONCLUSIONS Our results give the evidence that the increase of O(6)-methylguanine-DNA Methyltransferase mRNA expression caused by methylation changes in recurrence may be associated with chemoresistance in the recurrent glioma.